π
|
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
81 auth.
I. Puzanov,
A. Diab,
K. Abdallah,
C. Bingham,
C. Brogdon,
R. Dadu,
L. Hamad,
S. Kim,
M. Lacouture,
N. LeBoeuf,
D. Lenihan,
C. Onofrei,
V. Shannon,
R. Sharma,
A. Silk,
...
D. Skondra,
M. SuarezβAlmazor,
Y. Wang,
K. Wiley,
H. Kaufman,
M. Ernstoff,
J. Anderson,
Deborah Arrindell,
S. Andrews,
J. Ballesteros,
J. Boyer,
Daniel S Chen,
David Chonzi,
I. Cotarla,
R. Cunha,
M. Davies,
M. Dawson,
A. Dicker,
L. Eifler,
Andrew D. Ferguson,
C. Ferlini,
S. Frankel,
W. Go,
Celestine G. Gochett,
J. Goldberg,
P. Goncalves,
T. Goswami,
Nancy C. Gregory,
J. Gulley,
V. Hayreh,
Nicole Helie,
William C. Holmes,
J. hsu,
R. Ibrahim,
C. Larocca,
K. Lehman,
S. Ley-Acosta,
O. Lambotte,
J. Luke,
J. Mcclure,
E. Michelon,
Mary C. Nakamura,
K. Patel,
B. Piperdi,
Z. Rasheed,
D. Reshef,
J. Riemer,
C. Robert,
M. Sarkeshik,
Ann Saylors,
J. Schreiber,
K. Shafer-Weaver,
W. Sharfman,
E. Sharon,
R. Sherry,
C. Simonson,
C. Thomas,
John A Thompson,
E. Trehu,
D. Tresnan,
M. Turner,
Darshan Wariabharaj,
I. Waxman,
L. Wood,
Lin Zhang,
P. Zheng
|
10 |
2017 |
10 π
|